New options for diagnosing and treating acromegaly

Cleveland Clinic Journal of Medicine

Volumn 65, Issue 7, 1998, Pages 343-349

  Barkan, Ariel L ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b Novartis Pharmaceuticals Corporation

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; BROMOCRIPTINE; DOPAMINE RECEPTOR STIMULATING AGENT; GLUCOSE; GROWTH HORMONE; GROWTH HORMONE RELEASING FACTOR; OCTREOTIDE; PROTIRELIN; SOMATOMEDIN C; SOMATOSTATIN DERIVATIVE;

ACROMEGALY; ARTICLE; CLINICAL TRIAL; GROWTH HORMONE BLOOD LEVEL; GROWTH HORMONE RELEASE; HUMAN; HYPOPHYSIS ADENOMA; HYPOPITUITARISM; ORAL GLUCOSE TOLERANCE TEST; TREATMENT OUTCOME;

EID: 0031948965     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.65.7.343     Document Type: Article

References (6)

1. Thapar K, Kovacs K, Stefaneau L, et al. Overexpression of the growth-hormone-releasing hormone gene in acromegaly-associated pituitary tumors. Am J Pathol 1997; 151:769-784.
2. Bates AS, Van't Hoff W, Jones JM, Clayton RN. Does treatment of acromegaly affect life expectancy? Metab Clin Exper 1995; 44(suppl 1):1-5.
3. Ross DA, Wilson CB. Results of transsphenoidal microsurgery for growth hormone-secreting pituitary adenoma in a series of 214 patients. J Neurosurg 1988; 68:854-867.
4. Feek CM, Mclelland J, Seth J, et al. How effective is external pituitary irradiation for growth hormone-secreting pituitary tumors? Clin Endocrinol 1984; 20:401-408.
5. Jaffe CA, Barkan AL. Treatment of acromegaly with dopamine agonists. Endocrinol Metab Clin North Am 1992; 21:713-735.
6. Lambers SWJ, van der Lely A-J, de Herder WW, Hofland LJ. Octreotide. N Engl J Med 1996; 334:246-254.